On December 17, Jimin Credential announced that its wholly-owned subsidiary, Jiyu Pharmaceutical Innovation Technology and Drug Research Institute, independently developed the first three types of generic inhalation preparations—levalbuterol hydrochloride aerosol inhalation solution, which has been approved by the National Drug Administration.
The Center for Drug Evaluation (CDE) of the Bureau accepted
This is the second product that Jiminxin has entered the inhalation market after terbutaline sulfate atomized inhalation solution
Compared with ordinary salbutamol, the levosalbutamol hydrochloride aerosol inhalation solution removes the dextrorotate which is more selective for β1 receptors and brings side effects, and only retains the levosalbutamol which is more selective for β2 receptors
It has the characteristics of small side effects, good curative effect, and small dosage
As the active ingredient, levalbuterol has a strong affinity for β2 receptors, and β2 receptors are evenly distributed on the large, medium and small airways, so that the levalbuterol has a comprehensive effect on the smooth muscles of the large, medium and small airways, thus playing a consistent role in relaxing the airway smooth muscles
In 2019, Wang Chen, an academician of the Chinese Academy of Engineering and an expert in respiratory and critical care medicine, published research results in The Lancet, clarifying the prevalence of adult asthma in China: the prevalence of asthma in people aged 20 and above in China is 4.
Among them, the male prevalence rate is 4.
6%, the female prevalence rate is 3.
7%, and the total number of patients is 45.
7 million (25.
7 million males and 20 million females)
The latest data show that there are about 100 million people in China suffering from chronic obstructive pulmonary disease (COPD), and it has become the third leading cause of death among Chinese residents.
There is one COPD patient in every seven people aged 40 and over
Inhaled drugs are the first choice for the treatment of asthma and COPD, but the inhaled drug market in China is mostly occupied by multinational pharmaceutical companies.
In contrast, domestic inhaled drugs started late and have a small market share
Note: The original text has been deleted
Chen Wang, Jiangying Xu, Lan Yang, et al.
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study) a national cross-sectional study.
Lancet 2018 Vol 391 1706-1717.
Kewu Huang, Ting Yang, Jiangying Xu, et al.
Prevalence, risk factors, and management of asthma in China a national cross-sectional study.
Lancet 2019 Vol 394 407-418.